Free Trial

GoodRx (GDRX) Stock Forecast & Price Target

$8.25
-0.12 (-1.43%)
(As of 07/17/2024 ET)

GoodRx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 20 Wall Street analysts who have issued ratings for GoodRx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 7 have given a hold rating, and 12 have given a buy rating for GDRX.

Consensus Price Target

$9.32
12.92% Upside
High Forecast$16.00
Average Forecast$9.32
Low Forecast$4.50

According to the 20 analysts' twelve-month price targets for GoodRx, the average price target is $9.32. The highest price target for GDRX is $16.00, while the lowest price target for GDRX is $4.50. The average price target represents a forecasted upside of 12.92% from the current price of $8.25.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
3 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.32$9.32$8.78$7.94
Forecasted Upside12.92% Upside21.39% Upside16.22% Upside34.56% Upside
Get GoodRx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.

GDRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GDRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GoodRx Stock vs. The Competition

TypeGoodRxMedical CompaniesS&P 500
Consensus Rating Score
2.55
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.06% Upside1,213.28% Upside7.69% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/10/2024Morgan Stanley
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.50+11.11%
5/23/2024Royal Bank of Canada
4 of 5 stars
 UpgradeSector Perform ➝ Outperform$8.00 ➝ $10.00+38.89%
5/20/2024Barclays
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$9.00 ➝ $10.00+34.23%
5/16/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$14.00 ➝ $16.00+95.36%
5/16/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Ransom
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$10.00+37.55%
4/10/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSector Weight ➝ Overweight$9.00+33.53%
3/25/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.00+51.98%
3/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$5.00 ➝ $8.00-3.50%
3/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$6.50 ➝ $7.50-3.72%
3/1/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$7.50 ➝ $8.00+2.70%
3/1/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$7.00 ➝ $10.00+28.37%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$8.00+25.39%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$8.00 ➝ $4.50-32.84%
8/10/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$8.00 ➝ $10.00+18.62%
8/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$6.00 ➝ $8.00-5.10%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$7.00 ➝ $8.00-4.88%
8/10/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$7.00 ➝ $10.00+25.94%
8/10/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$7.00 ➝ $11.00+38.54%
8/10/2023DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Simmons
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$9.50+19.65%
11/16/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$6.50+29.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:34 PM ET.

GDRX Forecast - Frequently Asked Questions

What is GoodRx's forecast for 2024?

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for GoodRx is $9.32, with a high forecast of $16.00 and a low forecast of $4.50.

Should I buy or sell GoodRx stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There is currently 1 sell rating, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GDRX shares.

Does GoodRx's stock price have much upside?

According to analysts, GoodRx's stock has a predicted upside of 21.39% based on their 12-month stock forecasts.

Has GoodRx been upgraded by Wall Street analysts recently?

Over the previous 90 days, GoodRx's stock had 2 upgrades by analysts.

What analysts cover GoodRx?

GoodRx has been rated by research analysts at Barclays, Morgan Stanley, Raymond James, Royal Bank of Canada, and TD Cowen in the past 90 days.

Do Wall Street analysts like GoodRx more than its competitors?

Analysts like GoodRx less than other "medical" companies. The consensus rating score for GoodRx is 2.55 while the average consensus rating score for "medical" companies is 2.71. Learn more on how GDRX compares to other companies.


This page (NASDAQ:GDRX) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners